KEYTRUDA 25 mg/mL concentrate for solution for infusion, TransCon TLR7/8 Agonist
TCTLR-101
Phase 2 small_molecule active
Quick answer
KEYTRUDA 25 mg/mL concentrate for solution for infusion, TransCon TLR7/8 Agonist for Cancer is a Phase 2 program (small_molecule) at Pharma Mar S.A. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pharma Mar S.A.
- Indication
- Cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active